Introduction: Vernal keratoconjunctivitis (VKC) is a chronic, recurrent, bilateral inflammatory disease showing exacerbations during the spring and summer seasons, affecting young children. Present study was conducted with the aim of comparing the efficacy of cyclosporine 0.05% with olopatadine 0.1% in recalcitrant patients of VKC.
Materials and methods: A prospective randomized controlled trial was performed on 40 eyes (20 patients of recalcitrant VKC) during the period of May 2015 to September 2015. A short course of mild steroid was given for 5 days to all patients as they presented with acute exacerbation of recalcitrant VKC.
Left eye of each patient received topical cyclosporine 0.05%, which is a nonsteroidal immunomodulator, twice daily, and right eye of the same patient received olopatadine 0.1%, which has a dual action, i.e., mast cell stabilizer action as well as antihistaminic activity, twice daily for a period of 3 months. Grading of signs and symptoms was done at the time of presentation and at 2 weeks, 1 month, and 3 months interval.
Results: When compared with baseline, scores for signs and symptoms at 2 weeks reduced significantly for both cyclosporine and olopatadine. However, at 3 months, scores as regards signs and symptoms were found to be lower in cyclosporine as compared with olopatadine eyes.
Conclusion: Cyclosporine 0.05% was found to be equally effective in treating signs and symptoms as olopatadine in the early phase of the treatment. But, a significant improvement was noted in cyclosporine eyes as compared with olopatadine eyes in the late period.
Keywords: Immunomodulator, Mean symptom score, Nonsteroidal, Recalcitrant.
How to cite this article: Goyal E , D evendra J , G upta P. Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis. Int J Adv Integ Med Sci 2016;1(4):139-142.
Source of support: Nil
Conflict of interest: None